Brittany Herrin, DO
Family Medicine · Saint Louis, MONPI 1124548102
Payments from drug & device makers
Across 223 payments — averaging $34.16 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$2K
- Amgen$1K
- AstraZeneca$887
- Axsome Therapeutics, Inc.$366
- Novo Nordisk$328
- Pfizer$233
- plus $2K from 30 others
What the payments were for
- Food & beverage$7,54199%
- Education$771%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 107 | $2,260 |
| Amgen | 36 | $1,053 |
| AstraZeneca | 13 | $887 |
| Axsome Therapeutics, Inc. | 5 | $366 |
| Novo Nordisk | 5 | $328 |
| Pfizer | 8 | $233 |
| Bayer | 2 | $228 |
| Merck | 3 | $177 |
| Medtronic | 1 | $158 |
| Sumitomo Pharma America, Inc. | 2 | $138 |
| Neurocrine Biosciences, Inc. | 3 | $135 |
| Nevro Corp. | 1 | $127 |
| Idorsia Pharmaceuticals US Inc | 1 | $125 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 2 | $125 |
| Teva Pharmaceuticals USA, Inc. | 1 | $119 |
| Lilly USA, LLC | 2 | $118 |
| Otsuka America Pharmaceutical, Inc. | 2 | $118 |
| Abbott | 7 | $115 |
| Boehringer Ingelheim | 1 | $110 |
| Alkermes, Inc. | 1 | $109 |
| Phathom Pharmaceuticals, Inc. | 1 | $104 |
| Lundbeck LLC | 3 | $97 |
| Stryker | 1 | $94 |
| Biohaven Pharmaceuticals, Inc. | 2 | $79 |
| Exact Sciences | 2 | $34 |
| Convatec Inc. | 1 | $23 |
| Viatris Specialty LLC | 1 | $22 |
| Rhodes Pharmaceuticals L.p. | 1 | $20 |
| Biohaven Pharmaceutical Holding Company Ltd. | 1 | $20 |
| Novartis | 1 | $17 |
| Neurelis, Inc. | 1 | $15 |
| Dexcom, Inc. | 1 | $15 |
| Exeltis, USA Inc. | 1 | $14 |
| Kowa Pharmaceuticals America, Inc. | 1 | $14 |
| Valinor Pharma, LLC | 1 | $13 |
| Organon | 1 | $10 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$7,618 in reported general payments places this provider in the 90th percentile of 2,203 family medicine providers in Missouri.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 286 | $132,646 |
| MounjaroTirzepatide | 90 | $102,674 |
| Humira(Cf)Adalimumab | 13 | $97,160 |
| VraylarCariprazine Hcl | 47 | $78,834 |
| OzempicSemaglutide | 74 | $76,314 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 94 | $70,428 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 55 | $41,987 |
| FarxigaDapagliflozin Propanediol | 41 | $41,685 |
| RexultiBrexpiprazole | 59 | $40,205 |
| TrulicityDulaglutide | 23 | $39,525 |
| JardianceEmpagliflozin | 50 | $32,856 |
| XareltoRivaroxaban | 41 | $28,507 |
| EntrestoSacubitril/Valsartan | 33 | $20,761 |
| RybelsusSemaglutide | 12 | $19,476 |
| MyrbetriqMirabegron | 30 | $12,300 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieHumira(Cf), Vraylar | $2,260 | $175,99360 claims |
| Lilly USA, LLCMounjaro, Trulicity, Humalog | $118 | $146,669135 claims |
| PfizerEliquis | $233 | $132,646286 claims |
| Novo NordiskOzempic, Rybelsus | $328 | $95,79086 claims |
| AstraZenecaBreztri Aerosphere, Farxiga | $887 | $83,67296 claims |
| Boehringer IngelheimJardiance, Spiriva Respimat | $110 | $44,70673 claims |
| Otsuka America Pharmaceutical, Inc.Rexulti | $118 | $40,20559 claims |
| NovartisEntresto | $17 | $20,76133 claims |
| MerckJanuvia | $177 | $10,10925 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 2,203 family medicine providers in Missouri.
Other family medicine in Saint Louis
- Rupal TrivediSaint Louis$10.6M
- Emily DoucetteSaint Louis$155K
- Michael DonovanSaint Louis$78K
- Jarad SchwartzSaint Louis$36K
- Christina RobinsSaint Louis$27K
- Michael SpeziaSaint Louis$26K
- Amanda BooneSaint Louis$17K
- David GlickSaint Louis$17K
- Timothy JenningsMaryland Heights$30.2M
- William HowittSpringfield$19.9M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.